in neuromuscular diseases in neuro-ophthalmological diseases


We are a Swiss specialty pharmaceutical company committed to developing medicines to meet the needs of patients living with mitochondrial disorders and other rare diseases.

Read more>>

About Mitochondrial Diseases

At Santhera, we are passionate about providing treatment options for patients with rare mitochondrial diseases, specifically in the area of neuromuscular and neuro-ophthalmological conditions – diseases that have a severe impact on the lives of affected children and adults.

Read more>>
Health Care Professionals

Our medicines

Our focus is on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options. In September 2015, we received our first European Marketing Authorization for Raxone® in the treatment of patients with Leber’s hereditary optic neuropathy.

Read more>>
Investors & Media

Tools and Resources

The Investor and Media center provides information and resources for investor and media communities.

Read more>>

Working @Santhera

Santhera is a dynamic and international employer looking for colleagues who are talented, engaged and committed to growing the organization through the work that they do.

Read more>>

Latest News

Earlier press releases can be found here.
To subscribe to our News Feed, please click here.